Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 16/20 | 0.67 |
| ▸ | EDNRA | P25101 | 16/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.67 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228355 | 0.91 | EDNRB (0.72) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL15998733 | 0.89 | EDNRB (0.56) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL14751497 | 0.89 | EDNRB (0.59) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL12228356 | 0.85 | EDNRB (0.71) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL10316293 | 0.82 | EDNRB (0.71) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL4197434 | 0.82 | EDNRB (0.71) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL4197423 | 0.82 | EDNRB (0.71) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL13215612 | 0.82 | EDNRB (0.71) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Ambrisentan SCHEMBL20769813 | 0.80 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Ambrisentan SCHEMBL3023434 | 0.80 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040698-B2 | Method for preparing optically pure (+)-ambrisentan and (+)-darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-8962832-B2 | Process for the preparation of ambrisentan and novel intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2015-02-24 | — | — | US | disclosed |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-04 | — | — | US | disclosed |
| US-20130184490-A1 | PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID | NATCO PHARMA LIMITED (IN) | 2013-07-18 | — | — | US | disclosed |
| US-8404840-B2 | Process for the preparation of endothelin receptor antagonists | MSN LABORATORIES LIMITED (IL) | 2013-03-26 | — | — | US | disclosed |
| US-20130060031-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN | NATCO PHARMA LIMITED (IN) | 2013-03-07 | — | — | US | disclosed |
| US-20130060031-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN | NATCO PHARMA LIMITED (IN) | 2013-03-07 | — | — | US | disclosed |
| US-20120184573-A1 | PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | MSN LABORATORIES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| WO-2011114338-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN | NATCO PHARMA LIMITED (IN) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060031-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN | AGTR2, PDE7A, ACVR1B | EDNRB 4/4885EDNRA 10/4885NR1I2 3650/4885 |
| US-20130184490-A1 | PROCESS TO PREPARE S-2-HYDROXY-3-METHOXY-3,3-DIPHENYL PROPIONIC ACID | PAH, TGFB2, TGFBR2 | EDNRB 29/4885EDNRA 26/4885NR1I2 2862/4885 |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 2109/4885 |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | AKR1D1, AKR1C2, AKR1C1 | EDNRB 47/4885EDNRA 30/4885NR1I2 2176/4885 |
| US-20120184573-A1 | PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | ACVR1, ACVR1B, CYP11B1 | EDNRB 7/4885EDNRA 27/4885NR1I2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.